Global Dengue Vaccine Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2030

Global Dengue Vaccine Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2030

Global Dengue Vaccine Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2030

The Global Dengue Vaccine Market was valued around US $390.55 million in 2022 and is expected to reach US $1292.20 million by 2030 with a CAGR of 16.13% during the forecast period.

The World Health Organisation (WHO) describes dengue as a virus infection that is spread to people via the bite of an infected mosquito (DENV). It does not transfer directly from person to person and is not infectious. Specifically designed to offer defence against the four different serotypes of the dengue virus—serotypes 1, 2, 3, and 4—dengue vaccinations are intended to prevent the dengue disease.

Reputable institutions like the World Health Organisation (WHO), the U.S. Food and Drug Administration (FDA), the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA), the Pan American Health Organisation (PAHO), the European Medicine Agency (EMA), and Brazil's National Health Surveillance Agency (ANVISA) have all advised against dengue vaccination for anyone living in or visiting areas where dengue fever is a possibility. As of October 30, 2022, Sanofi Pasteur's Dengvaxia and Takeda's QDENGA are the two approved dengue vaccines that are accessible in several nations.

The prevalence of dengue has significantly increased worldwide in the last several decades. Dengue fever is the world's fastest-spreading mosquito-borne illness and one of the top 10 dangers to global health, according to the World Health Organisation. Over the past 50 years, the incidence of dengue has increased thirtyfold worldwide, with severe cases accounting for the majority of serious disease and deaths in some Asian and Latin American nations. Countries in Southeast Asia with high dengue fever incidences include Thailand, Indonesia, and the Philippines. Similar epidemics have occurred in several American nations, including as Brazil, Mexico, and Colombia. Insecticides are used to restrict the mosquito population, and fewer water-holding containers that facilitate mosquito reproduction are key components of conventional dengue management techniques. In addition, wearing protective clothes and applying personal repellents might assist avoid mosquito bites. However, dengue outbreaks are still possible, and it is still difficult to achieve long-term drops in mosquito populations using these techniques. Consequently, immunisation is now viewed globally as a component of an integrated approach to prevention and control. Researchers and producers are striving to create vaccines against dengue that offer protection against all four strains of the virus. As a result, the growing number of dengue fever cases serves as a catalyst for the development of the dengue vaccine and will expand the dengue vaccine market internationally in the years to come.

Government initiatives and rising consumer awareness of hygiene and health issues are further drivers.

“Hospitals and pharmacies segment, by end-users, to be dominating market from 2023 to 2030.”

The market is segmented into government agencies, research labs, hospitals and pharmacies, and speciality clinics based on the end-users. The global dengue vaccine market was dominated by pharmacies and hospitals in 2022, and this trend is anticipated to continue during the forecast period. In 2022, this category made up almost 43% of the total. The main healthcare facilities in charge of managing and treating dengue fever cases are hospitals and clinics. By giving the dengue vaccine, they either lessen the severity of the illness in those who have received the shot or assist prevent dengue cases from occurring. This has greatly impacted the market and will continue to do so in the years to come since it is essential in halting the spread of dengue and reducing its negative effects on public health. Due to the growing need for dengue vaccine worldwide, research laboratories will increase at the fastest rate during the projection period, with a CAGR of almost 20%. There is an urgent need to develop additional dengue vaccinations in order to combat the dengue virus because there are currently only two accessible, and they are not available everywhere. As a result, research into new vaccines is expanding in labs, which will increase market share.

“North America to be largest region in Dengue Vaccine Market.”

The market is segmented geographically into North America, Europe, Asia-Pacific, and other regions. With a about 53% market share in 2022, North America dominated the dengue market. The main reasons for North America's strong market share are rising knowledge of the dengue vaccine and its accessibility, affordability, and availability in the United States.

With a CAGR of over 22% over the projection period, APAC will expand at the fastest rate because of the continuous efforts being made by many institutions and organisations to produce new dengue vaccines. Additionally, the existence of developing nations where dengue is widespread creates a profitable market for dengue vaccine producers to sell the vaccine.

Dengue Vaccine Competitive Landscape

The competitive landscape of the Dengue Vaccine Market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Dengue Vaccine technology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Dengue Vaccine Market is highly competitive, with numerous companies vying for market share. Prominent companies in the Dengue Vaccine Market include:

Major Players:

Sanofi Pasteur

Takeda Pharmaceuticals

Others

Sanofi Pasteur and Takeda are the two companies have licensed dengue vaccines on the market, creating a highly concentrated market for dengue vaccines worldwide.

The market is dominated by Sanofi Pasteur. Sanofi Pasteur unveiled the first dengue vaccination in 2015. On May 1, 2019, the U.S. FDA approved Dengvaxia for use in children aged 9 to 16 who have laboratory-confirmed past dengue virus infection and reside in a place where dengue is common (the U.S. territory of American Samoa, the U.S. Virgin Islands, and Puerto Rico). The FDA accepted Sanofi Pasteur Inc.'s request to augment the Dengvaxia Biologics License Application on January 22, 2020. The only dengue vaccine that the American CDC's Advisory Committee on Immunisation Practices (ACIP) recommends for regular use is dengvaxia.

Takeda Pharmaceuticals offers the authorised tetravalent dengue vaccine QDENGA® (TAK-003). Any of the four dengue virus serotypes that can cause dengue fever or severe dengue is prevented by this vaccination. The dengue serotype two virus, which provides the genetic basis for all four serotypes of dengue, is the basis for QDENGA.

Recent Developments:

July 11, 2023: The U.S. Food and Drug Administration (FDA) has granted a supplement Biologics License Application (sBLA) for Dengue Tetravalent Vaccine, Live (Dengvaxia) in order to increase access to dengue vaccines.

July 11, 2023: Takeda has opted to withdraw its application for TAK-003, a potential dengue vaccine, from the FDA following an extensive examination. The FDA requested more information that the phase 3 TIDES studies, which were used to support the application, were unable to obtain, and this led to the conclusion. The business concluded that the present review cycle would not allow it to meet the agency's requirements.

May 18, 2023: Panacea and Serum Institute of India (SII), two biotech businesses, have partnered with the Indian Council of Medical Research (ICMR), India's highest authority for the development, management, and advancement of biomedical research, to carry out phase-III trials of their dengue vaccines.

TetraVax-DV (V180) on December 16, 2022 The V180 (Butantan-DV and TV003) adjuvanted, tetravalent subunit dengue vaccine candidate, developed by Merck & Co. and Instituto Butantan, consists of shortened versions of envelope proteins (DEN-80E), produced from strains of all four dengue virus serotypes. A phase 3 clinical investigation carried out in Brazil found that the V180 vaccination was 79.6% effective in preventing dengue. There were no significant dengue cases among the participants during this time.